By Jennifer Ahlstrom | Posted - Jun 4th, 2015





Refusal To Prioritize Medical Research A National Crisis. What Can We Do About It?

The lack of NIH funding for multiple myeloma and cancer in general results in fewer advances and longer timelines. A recent article by Greg Brozeit on shows that medical research for critical diseases is suffering as a whole.  Why the lack of priority? Greg explains the problem:

Consider, for example, that cancer will soon overtake heart disease as the primary killer of Americans. One of two males and one of three females will be diagnosed with a type of cancer during their lives. In 2015, that will translate into 1,658,370 new cases and 589,430 deaths.

Yet funding for the National Institutes of Health has remained relatively stagnant since its budget was doubled in 1998-2003 from $13.5 billion to $27 billion.  The last budget passed by Congress includes slightly more than $30 billion for NIH, the eleventh year in a row that it has remained relatively stagnant.

Taken together, this neglect actually has translated into significant cuts after factoring in inflation and has had devastating consequences. Less NIH research activity is taking place today than in 2003.

NIH is the fuel that runs the engines of research in many medical institutions throughout the nation.

How does this impact future discoveries for multiple myeloma and other cancers? Read more from Greg here.

How can myeloma patients and its community bridge this critical gap? Learn more about the game-changing Myeloma Crowd Research Initiative at

To learn more about how to start a team on the MCRI page to help us find a cure for myeloma, click here.


Jennifer Ahlstrom
About the Author

Jennifer Ahlstrom - Jenny A - Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical trials. Founder of Myeloma Crowd, Myeloma Crowd Radio, HealthTree and the CrowdCare Foundation.


Add a Comment



Thanks to our Myeloma Crowd Community sponsors:

.                         .       .